Due to our years of experience in genetic T cell engineering field, Creative Biolabs now provides T cell receptor (TCR) service for both clinical diagnostics and immunotherapy development against various cancers.
Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which is a major public health problem all over the world and is the second most common cause of death in the United States according to the mortality data collected by National Center for Health Statistics. It is reported that 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States in 2016. Recently, reprogramming T-cell populations by T-cell receptor (TCR) gene transfer> is emerging as a new therapeutic tool for adoptive tumor immunotherapy which achieved desired specificity and efficacy target cancers in several clinical trials. TCR gene therapy has a great deal of advantages compared with the conventional cellular transfer therapy and vaccine therapy using peptides of the cancer antigens. It circumvents the demanding process of in vitro generation of large numbers of specific immune cells and it allows the use of a set of particularly effective TCR genes in large patient groups. By employing TCR gene transfer therapy, it is possible to determine the effective doses of infused cells and also to control the patient's immune background in a different way.
Our high-affinity TCR technology based on screening and isolating specific naturally-occurring TCR on T cells from healthy donor people via affinity binding an antigen/major histocompatibility complex(MHC) of interest, or through engineering a specific T cell receptor by using recombinant technology. Subsequently, we can express this T cell receptor in T lymphocytes, which enable these cells to recognize and bind the specific MHC/antigen complex. One of the major advantages of this approach is that these T cells can recognize intracellular antigens expressed inside the target cells. Furthermore, as these TCRs are derived from human, which makes the reinfused T cells a much lower immunogenicity.
Our sophisticated strategies and first-class TCR technology platform can provide customers high-affinity TCR products with competitive price. Creative Biolabs has the capability to identify or construct T-cell receptors binding various tumor-associated antigens (TAAs), such as MART-1, gp100, NY-ESO-1, MAGE antigens and carcinoembryonic antigen (CEA), with optimal affinity to meet your specific development goal of adoptive T-cell therapy of cancers.
Advances in Passive Immunization Research and Application: 2012 Edition
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved